CSIMarket Company Name, Ticker, Suppliers, else..
 
Plus Therapeutics Inc   (NASDAQ: PSTV)
 
Price: $3.8380 $3.84 %
Day's High: $3.9549999237060547 Week Perf: 10.61 %
Day's Low: $ 3.77 30 Day Perf: -4.05 %
Volume (M): 67,471 52 Wk High: $ 23.50
Volume (M$): $ 0 52 Wk Avg: $9.00
Open: $3.78 52 Wk Low: $2.90



 Market Capitalization (Millions $) 26
 Shares Outstanding (Millions) 7
 Employees 28
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -26
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 1

Business Description


Plus Therapeutics Inc is a biotechnology company that specializes in developing and commercializing innovative, targeted therapies for rare and difficult-to-treat cancers. Their focus is on creating novel drugs that can potentially improve outcomes for patients with limited treatment options. They aim to combine advanced drug delivery technologies with cutting-edge science to deliver more effective and personalized treatments.


   Company Address: 6420 LEVIT GREEN BOULEVARD HOUSTON 77021 TX
   Company Phone Number: 255-7194   Stock Exchange / Ticker: NASDAQ PSTV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CATX        0.64% 
UEEC        82.33% 
AGEN        7.57% 
IMVT   -4.73%    
• View Complete Report
   



Shares

Plus Therapeutics Secures $15 Million in Private Placement and Launches Share Repurchase Program, Signaling Strong Financial Strategy,

Published Tue, Mar 4 2025 7:07 PM UTC

Plus Therapeutics Secures $15 Million in Private Placement Funding Amid Share Repurchase ProgramIn a significant development for Plus Therapeutics, Inc. the clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics, the firm has secured approximately $15 million in gross proceeds from a private placement. This strategic move follows a previous an...
Management Changes

Plus Therapeutics: Navigating Leadership Changes Amidst Mixed Financial Indicators

Published Mon, Feb 24 2025 12:30 PM UTC

In an evolving landscape of biopharmaceutical innovation, Plus Therapeutics Inc. is gripping attention, particularly with the recent appointment of new leadership within its CNSide Diagnostics subsidiary. This strategic move comes at a critical juncture for the company, as it contends with a notable decline in its stock performance. Over the past 90 days, the company’s sha...
Clinical Study

Rising Hope in Neuro-Oncology Plus Therapeutics’ Revolutionary Approach to Leptomeningeal Metastases Shines...

Published Mon, Nov 25 2024 12:30 PM UTC

At the recently concluded Society for Neuro-Oncology (SNO) Annual Conference in 2024, Plus Therapeutics presented compelling interim data from its ReSPECT-LM Phase 1 trial, examining the efficacy of Rhenium-186 nanoLiposome (186RNL) in patients suffering from leptomeningeal metastases. This groundbreaking research has the potential to reshape the therapeutic landscape for a ...
Clinical Study

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide Cerebrospinal Fluid Assay in Patients wi...

Published Thu, Nov 21 2024 12:30 PM UTC

Unlocking New Horizons in Neuro-Oncology: Plus Therapeutics Pioneering Advances in Leptomeningeal Metastases and Glioblastoma MultiformePlus Therapeutics is making notable strides in the realm of neuro-oncology, showcasing their ground-breaking work across two pivotal areas: leptomeningeal metastases and glioblastoma multiforme (GBM). The company has recently shared signif...
Clinical Study

Plus Therapeutics is pushing the frontiers of oncology with its latest research and clinical trial data, of...

Published Fri, Nov 22 2024 12:30 PM UTC

Revolutionizing Cancer Treatment: Plus Therapeutics Groundbreaking Advances in CNSide Assays and ReSPECT Clinical Trials for CNS Metastases Plus Therapeutics is pushing the frontiers of oncology with its latest research and clinical trial data, offering hope and innovative solutions to patients grappling with challenging metastatic conditions. At two prestigious conferences...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 6.30
Price to Sales (Expected) -
Price to Book 4.85
PEG (TTM) -

Financial Strength Current
Quick Ratio 1
Working Capital Ratio 1.37
Leverage Ratio (MRQ) 1.57
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.41 $
Revenues (TTM) 0.61 $
Cash Flow (TTM) 0.95 $
Cash 1.24 $
Book Value 0.79 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 150,107
Net Income per Employee (TTM) -931,714
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.24

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -2203.65 %
Net Margin (MRQ) -2191.24 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Plus Therapeutics Inc's Segments
Grant    340.63 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.